BridgeMD
New treatment option for Laparoscopic Cholecystectomy
Official title Dexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum
ClinicalTrials.gov ID: NCT06575179
What this study is testing
What is Dexmedetomidine low-dose?
Dexmedetomidine low-dose is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for laparoscopic cholecystectomy.
Also referred to as dexmedetomidine hydrochloride Injection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical trial aims to learn the impact of dexmedetomidine on the minimum alveolar concentration blunting the adrenergic response (MAC-BAR) of sevoflurane to carbon dioxide pneumoperitoneum in patients undergoing laparoscopic cholecystectomy. It will also learn about the effect of dexmedetomidine on hemodynamic parameters.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- 1\. Aged 18-45 years.
- 2\. American Society of Anesthesiologists (ASA) grade I - II.
- 3\. Patients undergoing elective laparoscopic cholecystectomy.
You likely can't join if
- 1\. Inability to provide informed consent;
- 2\. History of chronic pain or substance abuse;
- 3\. Pregnancy;
- 4\. Body mass index (BMI) ≥ 30 kg/m2;
- 5\. Known allergies to the study medications;
- 6\. Intake of medications within the last 72 hours that potential interfere with the determination of the MAC-BAR;
See the full eligibility criteria
- 1\. Aged 18-45 years.
- 2\. American Society of Anesthesiologists (ASA) grade I - II.
- 3\. Patients undergoing elective laparoscopic cholecystectomy.
- 1\. Inability to provide informed consent;
- 2\. History of chronic pain or substance abuse;
- 3\. Pregnancy;
- 4\. Body mass index (BMI) ≥ 30 kg/m2;
- 5\. Known allergies to the study medications;
- 6\. Intake of medications within the last 72 hours that potential interfere with the determination of the MAC-BAR;
- 7\. Any other condition deemed exclusionary by the investigators.
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.